Considering that TP53 as well as AURB were induced by fosaprepitant treatment in our experiments, agents activating or stabilizing TP53 as well as AURB kinase inhibitors may also act synergistically with TACR1 inhibitors in neuroblastoma. The gene discussed is AURKB; the disease is neuroblastoma.